.png){kind=icon}
.png){kind=icon}
Return
The JAK1 Inhibitor Golidocitinib Boosts Therapeutic Potency of DLL3-Targeted CAR-T Therapy for Small Cell Lung Cancer
.png){kind=icon}
OA
AI
M
Y
F
Y
W
J
H
R
H
Y
S
L
E
Y
B
X
Y
C
钟
DOI：10.1016/j.phrs.2026.108347.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Small cell lung cancer (SCLC) is an aggressive malignancy with limited effective therapeutic options. DLL3-targeted CAR-T therapy shows promising anti-tumor potential but is often restricted by T-cell exhaustion, which impairs its long-term efficacy. In the present study, we found that golidocitinib, a highly selective JAK1 inhibitor, induces apoptosis in SCLC cells in vitro via inhibiting STAT3 phosphorylation and regulating apoptosis‑associated genes. It also reduced the expression of exhaustion markers in anti-DLL3 CAR-T cells, promoted the formation of memory T cell phenotypes, and enhanced CAR-T cell persistence both in vitro and in vivo. When combined with anti-DLL3 CAR-T therapy, golidocitinib significantly augmented anti-tumor efficacy in both in vitro cytotoxicity assays and in vivo models, without obvious organ toxicity. These findings collectively demonstrate the dual anti-tumor effects of golidocitinib, thus providing a novel and promising strategy for SCLC treatment.
Keywords:
SCLC
JAK1
golidocitinib
DLL3
CAR-T
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.5
Papers:
8.7K
Citations:
3.6W
Organization
Cited Papers